Trials / Conditions / Stage III Squamous Cell Carcinoma of the Nasopharynx

Stage III Squamous Cell Carcinoma of the Nasopharynx

23 registered clinical trials studyying Stage III Squamous Cell Carcinoma of the Nasopharynx.

Status	Trial	Sponsor	Phase
Completed	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511	Mayo Clinic	Phase 2
Withdrawn	Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra NCT01728480	Roswell Park Cancer Institute	Phase 1
Withdrawn	Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio NCT01674374	Roswell Park Cancer Institute	Phase 2
Terminated	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137	Stanford University	Phase 1
Completed	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177	University of Washington	Phase 1
Terminated	Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer NCT01254734	City of Hope Medical Center	N/A
Completed	L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609	University of Washington	N/A
Terminated	Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receivin NCT01682031	Roswell Park Cancer Institute	Phase 2
Terminated	Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Cau NCT00895245	University of Washington	Phase 2
Completed	Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) NCT00896181	Stanford University	Phase 2
Terminated	Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360	National Cancer Institute (NCI)	Phase 1
Completed	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429	Ohio State University Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435	National Cancer Institute (NCI)	Phase 2
Completed	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089	National Cancer Institute (NCI)	Phase 2
Completed	Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or NCT00410826	University of Washington	Phase 2
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362	National Cancer Institute (NCI)	Phase 1
Terminated	Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1